-
-
-
-
-
-
Momenta Pharmaceuticals Inc (Momenta) announced that it has entered into a definitive agreement with Johnson & Johnson (J&J). According to the agreement, J&J will acquire Momenta for USD 52.50 per share in an all-cash transaction.
-
The British drug-maker, AstraZeneca signed an exclusive deal with Beijing based Shenzhen Kangtai Biological Products Co., Ltd to manufacture a potential COVID-19 vaccine in mainland China.
-
Alembic Pharmaceuticals Limited announced that the Company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Vardenafil Hydrochloride Tablets, 2.5 mg (base), 5 mg (base), 10 mg (base), and 20 mg (base).
-
-
AbbVie announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to placebo, for all doses across the 12-week treatment period.
RECOMMENDED POSTS
Subscribe with us
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
